高收缩力与氧化应激驱动肥厚型心肌病中肌酸激酶功能障碍
该研究分析92例HCM患者和30例非衰竭对照的左心室组织,发现HCM心肌中肌丝和线粒体CK蛋白水平及活性显著降低,主要源于CK的氧化修饰。小鼠实验表明高收缩力诱导的线粒体H2O2升高导致心律失常和CK失活,而肌球蛋白抑制剂MYK-581可降低H2O2、减少心律失常并保护CK功能。
要点
- HCM患者心肌中肌丝和线粒体CK蛋白水平及活性显著降低,主要由氧化修饰所致。
- 高收缩力通过增加线粒体H2O2导致CK失活和细胞心律失常,靶向线粒体H2O2可保护。
- 肌球蛋白抑制剂MYK-581可降低H2O2、减少心律失常并保留CK功能。
核心结论
- 本研究揭示了HCM中高收缩力、线粒体活性氧与CK功能障碍之间的机制联系,形成能量代谢障碍的恶性循环。
- 通过肌球蛋白抑制靶向高收缩力和氧化应激,可恢复能量平衡并降低HCM心律失常风险。
研究设计与样本
- 分析92例HCM患者(伴或不伴致病性肌节变异)和30例非衰竭人类对照的左心室心肌组织。
- 使用mRNA分析、蛋白免疫印迹、酶活性测定、质谱和氧化还原敏感蛋白质组学测量CK亚型。
- 使用野生型、线粒体靶向过氧化氢酶过表达、CK敲除、HCM相关Mybpc3敲入和mito-roGFP2-Orp1小鼠模型的分离心肌细胞。
- 测试Ca2+增敏剂EMD-57033、CK抑制剂DNFB和肌球蛋白抑制剂MYK-581(mavacamten衍生物)的效果。
主要发现
- HCM患者心肌中肌丝和线粒体CK蛋白水平及CK活性显著降低,主要由于CK的氧化修饰。
- 在野生型和CK敲除小鼠心肌细胞中,EMD-57033诱导的高收缩力升高线粒体H2O2,导致细胞心律失常和CK失活。
- Mybpc3敲入心肌细胞中也观察到高收缩力诱导的氧化应激、心律失常和CK功能障碍。
- 线粒体靶向过氧化氢酶过表达小鼠对H2O2诱导(EMD-57033介导)的心律失常和CK功能障碍有保护作用。
- MYK-581处理Mybpc3敲入心肌细胞可降低高收缩力、减少H2O2产生和心律失常,并保留CK功能。
临床怎么用
- 肌球蛋白抑制剂(如MYK-581/mavacamten衍生物)可能通过降低高收缩力和氧化应激来恢复CK功能并减少心律失常风险。
- 线粒体靶向抗氧化策略(如过氧化氢酶过表达)在实验模型中可保护H2O2诱导的CK功能障碍和心律失常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder marked by left ventricular hypertrophy and hypercontractility. This excessive mechanical workload creates an energetic mismatch in which consumption exceeds production, leading to myocardial energy depletion. Although CK (creatine kinase) plays a key role in cardiac energy homeostasis, its involvement in HCM remains unclear. This study investigates how hypercontractility-driven mitochondrial stress and the resulting increase in mitochondrial H2O2 disrupt CK function in HCM. METHODS: CK function was analyzed using myocardial left ventricular tissue from 92 patients with HCM (with and without pathogenic sarcomere variants) and 30 non-failing human controls. Myofilament and mitochondrial CK isoforms were measured using mRNA analysis, protein immunoblotting, enzyme activity assays, mass spectrometry, and redox-sensitive proteomics. To explore links between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction, we used isolated cardiomyocytes from wild-type, mitochondrial-targeted catalase-overexpressing, CK knockout (myofilament and mitochondrial CK deletion), HCM-associated Mybpc3 knock-in, and mito-roGFP2-Orp1 mouse models. We also tested the effects of the Ca2+ sensitizer EMD-57033, the CK inhibitor 1-fluoro-2,4-dinitrobenzene (DNFB), and the myosin inhibitor MYK-581, a mavacamten derivative. RESULTS: Our analysis revealed significant reductions in myofilament and mitochondrial CK protein levels, as well as CK activity, in myocardium of patients with HCM, primarily because of oxidative modifications of CK. In isolated mouse cardiomyocytes from wild-type and CK knockouts, hypercontractility induced by EMD-57033 elevated mitochondrial H2O2, causing cellular arrhythmias and CK inactivation. Hypercontractility-induced oxidative stress, arrhythmias, and CK dysfunction were also observed in Mybpc3 knock-in cardiomyocytes. Mitochondrial-targeted catalase-overexpressing mice with enhanced H2O2 scavenging were protected against H2O2-induced (EMD-57033-mediated) arrhythmias and CK dysfunction. MYK-581 treatment in Mybpc3 knock-in cardiomyocytes reduced hypercontractility, lowered H2O2 production and arrhythmias, and preserved CK function. CK inhibition using DNFB in wild-type cardiomyocytes elevated mitochondrial H2O2 levels and triggered cellular arrhythmias. This mitochondrial oxidation was independently confirmed in mito-roGFP2-Orp1 cardiomyocytes exposed to DNFB. Mitochondrial-targeted catalase-overexpressing mice were protected from DNFB-induced oxidative stress and arrhythmogenic events. CONCLUSIONS: This study reveals a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction in HCM, perpetuating a cycle of energetic dysfunction. Targeting hypercontractility and oxidative stress through myosin inhibition offers a strategy to restore energy balance and reduce arrhythmic risk in HCM.
引用
- Xu A, Weissman D, Ermer KJ, et al. Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. Circulation. 2025. PMID: 41111389. doi:10.1161/CIRCULATIONAHA.125.074120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。